Alnylam Pharmaceuticals, INC Form 4 insider transactions

Alnylam Pharmaceuticals Director David E.I. Pyott executed a series of stock transactions under a pre-arranged Rule 10b5-1(c) trading plan.

Alnylam Pharmaceuticals director Benjamin Cravatt acquired stock options valued at $295.63 per share, with vesting over three years.

Director Charles Elliott Sigal acquired 671 restricted stock units and 1,441 stock options as part of an annual equity incentive grant.

Director Amy W. Schulman was granted 838 restricted stock units and 1,802 stock options as part of annual compensation.

Director Colleen F. Reitan was granted 671 restricted stock units and 1,441 stock options as part of Alnylam Pharmaceuticals' incentive plan.

Alnylam Pharmaceuticals Director David E.I. Pyott acquired 671 restricted stock units and 1,441 stock options as part of an annual equity grant.

Director Peter N. Kellogg acquired 671 restricted stock units and 1,441 stock options as part of an annual equity incentive grant.

Director Margaret A. Hamburg was granted 671 restricted stock units and 1,441 stock options by Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals director Olivier Brandicourt was granted 671 restricted stock units and 1,441 stock options as part of annual compensation.

Director Stuart A. Arbuckle was granted 671 restricted stock units and 1,441 stock options as part of annual compensation.

Director Amy W. Schulman of Alnylam Pharmaceuticals, Inc. reported a transaction involving the exercise of stock options and the subsequent sale of common stock.

Alnylam Pharmaceuticals reports a Form 4 filing detailing stock transactions by Chief Human Resources Officer Melissa McLaughlin.

Alnylam Pharmaceuticals EVP Chief R&D, Pushkal Garg, reported sales of common stock totaling 4,713 shares for tax obligations and under a pre-arranged trading plan.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet sold 2,933 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Alnylam Pharmaceuticals' EVP and CFO, Jeffrey V. Poulton, sold common stock on March 4, 2026, to cover tax withholding obligations from restricted stock unit vesting.

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, sold 2,309 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Alnylam Pharmaceuticals' CSO & EVP, Kevin Fitzgerald, reported sales of common stock totaling 1,291 shares for tax obligations and under a pre-arranged 10b5-1 trading plan.

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, reported the acquisition of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Alnylam Pharmaceuticals' EVP Chief R&D, Pushkal Garg, reported the acquisition of new equity awards and sales of common stock, including tax-related sell-to-cover transactions and sales under a pre-arranged 10b5-1 plan.

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, reported a series of stock acquisitions and sales, including RSU grants, option grants, and sales for tax obligations and a 10b5-1 plan.

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, reported the grant of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Alnylam Pharmaceuticals' EVP, CLO, and Secretary, Bryan Supran, was granted 1,539 restricted stock units and options for 3,381 shares.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reported new equity awards, including restricted stock units, stock options, and performance stock units, alongside sales of shares to cover tax obligations.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet acquired 5,921 shares of common stock following the vesting of restricted stock units on February 27, 2026.

Alnylam Pharmaceuticals' EVP and CFO, Jeffrey V. Poulton, increased his direct beneficial ownership of common stock by 1,908 shares following the vesting of restricted stock units.

Alnylam Pharmaceuticals' EVP, Chief Commercial Officer, Tolga Tanguler, saw 1,666 restricted stock units vest and convert to common stock.

Alnylam Pharmaceuticals' EVP Chief R&D, Pushkal Garg, sold 4,627 shares of common stock following the vesting of 1,908 restricted stock units, all executed under a pre-arranged 10b5-1 trading plan.

Alnylam Pharmaceuticals' CSO & EVP, Kevin Fitzgerald, increased his beneficial ownership through a 20-year service award and 401(k) matching contributions.

ALNYLAM PHARMACEUTICALS' EVP Chief R&D, Pushkal Garg, reported the vesting of 3,800 performance-based stock units following the achievement of a $2.5 billion revenue target, alongside subsequent tax-related stock sales.

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reported the vesting of performance-based stock units and subsequent sale of shares to cover tax obligations.